Garcia-Foncillas Jesús, Bayle Arnaud, Arnold Dirk, Avouac Bernard, Awada Ahmad, de la Cruz-Merino Luis, Helland Åslaug, Lassen Ulrik, Laurent-Puig Pierre, Normanno Nicola, Rohrberg Kristoffer, Taieb Julien, Stenzinger Albrecht
University Cancer Institute & The Department of Oncology, University Hospital Fundacion Jimenez Diaz, Autonomous University, Madrid, Spain.
Bureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Future Oncol. 2025 Jun;21(14):1745-1752. doi: 10.1080/14796694.2025.2501523. Epub 2025 May 8.
The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a "roadmap to access" that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.
用于检测个体肿瘤分子和基因组特征的先进生物分子技术的出现，改变了肿瘤学护理模式，引入了经过验证的方法，这些方法可为匹配的靶向治疗提供治疗依据，并在个体患者层面预测反应。然而，获取这些技术受到多种障碍的阻碍，最显著的是价格和可获得性。其他障碍包括对现有技术缺乏了解、对价值的担忧，以及阻碍诊所或实验室关键操作的过时基础设施。先进生物分子检测的可及性障碍对患者护理至关重要，因为分子医学的新技术进展继续超过解决方案的实施速度。鉴于精准肿瘤学药物改善患者预后的已证实证据，了解这些技术所提供的价值势在必行。本叙述性综述的目的是描述现有的和新出现的获取障碍，并提出一个“获取路线图”，以促进急需的讨论，从而确定改善获取的解决方案。实施这些解决方案将提高对现有技术和治疗方法及其预后意义的认识，改善用于证明价值的证据收集，并加强临床和实验室基础设施及操作。
